世界の全身性エリテマトーデスの市場規模は、2023年に26億米ドルと評価され、2024年から2030年にかけて7.3%のCAGRで成長すると予測されます。自己免疫疾患の新規症例の増加、世界的なSLEの有病率の増加、早期診断の重要性に関する認識、全身性エリテマトーデス(SLE)の治療法の研究開発の増加が、市場の成長に影響を与える重要な要因です。近年、重篤な自己免疫疾患に関連する革新的な治療法の出現、SLEに関連する医薬品や治療法の入手可能性、多くの国での医療インフラの拡充が、この市場の成長を後押ししています。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Systemic Lupus Erythematosus Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Systemic Lupus Erythematosus Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political Landscape
3.4.2.2. Economic and Social Landscape
3.4.2.3. Technological Landscape
3.4.2.4. Environmental Landscape
3.4.2.5. Legal Landscape
Chapter 4. Systemic Lupus Erythematosus Market: Drug Class Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Systemic Lupus Erythematosus Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
4.3. Biologics
4.3.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Saphnelo (Anifrolumab)
4.3.3. Saphnelo (Anifrolumab) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.4. Benlysta (Belimumab)
4.3.5. Benlysta (Belimumab) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.6. Phase 3 Pipeline Products
4.3.7. Phase 3 Pipeline Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. TNF Inhibitors
4.4.1. TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. NSAIDs
4.5.1. NSAIDs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Corticosteroids
4.6.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Antimalarials
4.7.1. Antimalarials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Immunosuppressants
4.8.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Other Drug Classes
4.9.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Systemic Lupus Erythematosus Market: Route of Administration Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Systemic Lupus Erythematosus Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
5.3. Oral
5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Intravenous
5.4.1. Intravenous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Subcutaneous
5.5.1. Subcutaneous Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Other Route of Administration
5.6.1. Other Route of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Systemic Lupus Erythematosus Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Systemic Lupus Erythematosus Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacy
6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacy
6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacy
6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Systemic Lupus Erythematosus Market: Regional Estimates & Trend Analysis
7.1. Systemic Lupus Erythematosus Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. China Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. South Korea Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Systemic Lupus Erythematosus Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Novartis AG
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. GSK plc.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. F. Hoffmann-La Roche Ltd
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Pfizer Inc.
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Sanofi
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Lycera (Celgene)
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Bristol-Myers Squibb Company
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. ImmuPharma PLC
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Merck KgaA
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. AstraZeneca
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
8.4.11. UCB S.A.
8.4.11.1. Participant’s Overview
8.4.11.2. Financial Performance
8.4.11.3. Product Benchmarking
8.4.11.4. Recent Developments/ Strategic Initiatives
